Digest the Evidence Around Jorveza

April 2021

Jorveza (budesonide) orodispersible tabs will be the first treatment approved for eosinophilic esophagitis (EoE).

This chronic, inflammatory "asthma of the esophagus" can cause difficulty swallowing food, vomiting, abdominal pain, etc...and occurs in either adults or children.

Treating EoE often involves an Rx for inhaled steroids, such as budesonide nebules or fluticasone propionate MDI...but with directions to SWALLOW the dose, instead of inhale.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter Canada includes:

12 issues every year, with brief articles about new meds and hot topics
200+ CE courses, including the popular CE-in-the-Letter
Quick reference drug comparison charts
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get quote

COVID-19 Sort Through Growing Options for COVID-19 Vaccines
Liver Disease Help Manage Dose Adjustments in Liver Disease
HIV & AIDS Be Ready to Answer Questions About the New INSTI HIV Self Test
Bowel Preps Know the Ins and Outs of Bowel Preps
Respiratory & Allergy Digest the Evidence Around Jorveza
Diabetes Ensure Eligible Patients With Diabetes Are on a Statin
Immunosuppressives Be Alert for Rare Risks with Janus Kinase Inhibitors (Xeljanz, Etc)
Headache Monitor BP in Patients on Injectable CGRP Antagonists (Aimovig, Etc)
COVID-19 Put Inhaled and Oral COVID-19 Treatments in Perspective

Digest the Evidence Around Jorveza

Get concise advice on drug therapy, plus unlimited access to CE

Table of Contents